Form 4: Citius Oncology Director Acquires 250,000 Stock Options

Director Joel David Mayersohn of Citius Oncology, Inc. was granted 250,000 stock options on December 12, 2024.

Summary

• Joel David Mayersohn, a director at Citius Oncology, Inc., was granted 250,000 stock options on December 12, 2024.
• The exercise price of these options is $1.07 per share.
• The options will vest 100% on December 12, 2025, one year after the grant date, contingent on continuous service to the company.
• The options expire on December 12, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The grant of stock options to a director aligns their interests with the company's long-term success.
• The vesting period encourages continued service and commitment from the director.

Future Outlook

The director's stock options will vest in one year, contingent on continued service to the company.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the company's performance.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice across the biotechnology industry.
• The vesting period of one year is typical for such grants, aligning with industry norms for incentivizing long-term commitment.
• The exercise price of $1.07 is specific to Citius Oncology's stock price at the time of the grant and would need to be compared to similar grants at comparable companies to assess its relative value.

Stakeholder Impact

• The stock option grant may positively impact shareholder confidence by aligning director interests with company performance.

Key Dates

Keywords

stock options, director, insider trading, equity, Citius Oncology, CTOR, vesting